KRYS News and Press, Krystal Biotech Inc. From 06/03/23

2023-06-03 08:30:00 ET This year has been a good one for equity markets so far, but even by that standard, some stocks are doing incredibly well. That's the case with Krystal Biotech (NASDAQ: KRYS) , a mid-cap company that is already up 48% in 2023. As is often the case in this ...

Company to Deliver to Patients FDA-Approved Topical Treatment for Dystrophic Epidermolysis Bullosa (DEB) Announces Collaboration with Amedisys to Administer Treatment in the Home BANNOCKBURN, Ill., May 23, 2023 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health...

2023-05-22 12:53:27 ET Shares of Krystal Biotech (NASDAQ: KRYS) were up more than 15% Monday morning. The company announced on Friday that it had received Food and Drug Administration (FDA) approval for Vyjuvek (beremagene geperpavec-svdt) as the first therapy to treat dystroph...

Krystal Biotech, Inc. (NASDAQ: KRYS) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 15.72% on the day to $111.16. Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable ge...

2023-05-22 07:31:57 ET A biotechnology company, Krystal Biotech ( NASDAQ: KRYS ) entered into a securities purchase agreement for the sale of ~1.73M shares at $92.50 per share in a private placement to certain qualified institutional buyers. Gross proceeds are expecte...

PITTSBURGH, May 22, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the Company) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, today announced that it has entered into a securities purchase agreeme...

Dystrophic Epidermolysis Bullosa (DEB) is a serious rare genetic disease that affects the skin and mucosal tissues and is caused by one or more mutations in the COL7A1 gene, resulting in lack of production of functional type VII collagen (COL7) protein VYJUVEK is a topical gel that addres...

2023-05-18 14:09:46 ET Summary Krystal Biotech, Inc. is a promising gene therapy innovator that is benefitting from sector rotation. The lead gene therapy (B-vec) is designed to treat a debilitating skin condition coined dystrophic epidermolysis bullosa. Though B-vec has a sma...

2023-05-08 14:27:28 ET Summary Krystal Biotech, Inc. has a PDUFA date of May 19, 2023, established for the FDA to review B-VEC for potential U.S. marketing approval to treat patients with Dystrophic Epidermolysis Bullosa. There is potential European approval of B-VEC for the treat...

2023-05-08 08:43:08 ET Krystal Biotech press release ( NASDAQ: KRYS ): Q1 GAAP EPS of -$1.76 misses by $0.28 . Cash, cash equivalents, and investments totaled $355.5 million on March 31, 2023. For further details see: Krystal Biotech GAAP EPS of -$1.76 m...